World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ChiCTR
Last refreshed on: 18 April 2017
Main ID:  ChiCTR-TRC-12001935
Date of registration: 2012-02-12
Prospective Registration: No
Primary sponsor: Zhejinag University of Chinese Medicine
Public title: Effect of Detoxification, Removing Stasis and Nourishing Kidney Method on Promoting the Reduction of Prednisone in Treating SLE
Scientific title: Effect of Detoxification, Removing Stasis and Nourishing Kidney Method on Promoting the Reduction of Prednisone in Treating SLE
Date of first enrolment: 2008-01-12
Target sample size: Treatment Group:161;control group:161;
Recruitment status: Completed
URL:  http://www.chictr.org.cn/showproj.aspx?proj=7613
Study type:  Interventional study
Study design:  Randomized parallel controlled trial  
Phase:  III (Phase III study)
Countries of recruitment
China
Contacts
Name: Fan Yongsheng   
Address:  548 Binwen Road, Hangzhou, China 310053
Telephone: +86 0571 86613587
Email: fyszjtcm@163.com
Affiliation: 
Name: Xie Zhijun   
Address:  548 Binwen Road, Hangzhou, China 310053
Telephone: +86 13757132498
Email: xzj575@163.com
Affiliation:  Zhejinag University of f Chinese Medicine
Key inclusion & exclusion criteria
Inclusion criteria: Complying with four or more items in the SLE western medicine diagnosis standard; the patients accord with liver-kidney Yin deficiency toxic heat and blood stasis; the SLE patients in mild- moderate period (SLEDAI between 5 to 14); patients in the age between 18 and 60 years; patients who voluntary to enjoy the test and agree to sign informed consent certificates; patients did not use other related drugs within one week before experimental treatment.
Exclusion criteria: The illness in severe active period; current dosage of prednisone >1mg/kg.d; merge use other immunosuppressive agents beyond glucocorticoid; merge of the fatal damage to target organs; pregnant and lactating women and mental patients; can't tolerate the durgs of the study; diagnosesed as type VI of lupus nephritis or phase V of Chronic nephrosis.

Age minimum: 18
Age maximum: 60
Gender: Both
Health Condition(s) or Problem(s) studied
mild-to-moderate systemic lupus erythematosus
Intervention(s)
Treatment Group:treated with prednisone and Jieduquyuzishen recipe;control group:treated with prednisone;
Primary Outcome(s)
dosage of prednisone;SLEDAI;Blood routine;Stool routine;Urine routine;Blood biochemistry parameter;
Secondary Outcome(s)
TCM syndromes scores;SF-36;AE;
Secondary ID(s)
Source(s) of Monetary Support
State Ministry of Science and Technique
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history